PROMUS PREMIER: new everolimus-eluting stent

The study aims to evaluate clinical, angiographic and IVUS results of the new platinum chromium everolimus stent. The new design of the device has additional proximal connectors to enhance the longitudinal strength where distortion is more common. Included were 100 patients with de novo coronary lesions and a reference diameter of 2.5 to 4 mm and a length of

Conclusion: Technical success was high with clinical, angiographic and IVUS showing safety and efficacy without observing any stent deformation.

john_ormistron_europcr
John Ormistron.
2013-05-22

Original title: Clinical, angiographic and IVUS outcomes of the NG PROMUS clinical trial evaluating the novel Promus PREMIER stent. 

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...